Stacy Ku
Stock Analyst at TD Cowen
(3.88)
# 1,892
Out of 4,592 analysts
146
Total ratings
47.6%
Success rate
7.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stacy Ku
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| YARW Yarrow Bioscience | Initiated Coverage: Buy | n/a | $35.02 | - | 9 | Jul 27, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Buy | $17 | $14.88 | +14.25% | 15 | Jul 20, 2026 | |
| TNXP Tonix Pharmaceuticals Holding | Maintained: Buy | $22 | $10.01 | +119.78% | 3 | Jun 29, 2026 | |
| AVTX Avalo Therapeutics | Maintained: Buy | n/a | $18.25 | - | 4 | Jun 11, 2026 | |
| SLGL Sol-Gel Technologies | Initiated Coverage: Buy | n/a | $82.25 | - | 1 | May 29, 2026 | |
| TARA Protara Therapeutics | Rated: Buy | n/a | $3.92 | - | 14 | May 20, 2026 | |
| VRCA Verrica Pharmaceuticals | Maintained: Buy | $20 | $5.22 | +283.14% | 14 | May 12, 2026 | |
| LENZ LENZ Therapeutics | Maintained: Buy | $60 | $5.30 | +1,032.08% | 17 | May 11, 2026 | |
| BCRX BioCryst Pharmaceuticals | Maintained: Buy | $30 | $8.98 | +234.08% | 16 | May 6, 2026 | |
| SUPN Supernus Pharmaceuticals | Maintained: Buy | $65 | $44.63 | +45.64% | 20 | May 5, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | €310.00 → €305.00 | €217.88 | +39.99% | 23 | May 4, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $12 → $8 | $2.08 | +284.62% | 2 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $165 → $175 | $128.41 | +36.28% | 6 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $6.34 | - | 1 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | n/a | $18.44 | n/a | 1 | Feb 26, 2025 |
Yarrow Bioscience
Jul 27, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $35.02
Upside: -
Aurinia Pharmaceuticals
Jul 20, 2026
Maintained: Buy
Price Target: $17
Current: $14.88
Upside: +14.25%
Tonix Pharmaceuticals Holding
Jun 29, 2026
Maintained: Buy
Price Target: $22
Current: $10.01
Upside: +119.78%
Avalo Therapeutics
Jun 11, 2026
Maintained: Buy
Price Target: n/a
Current: $18.25
Upside: -
Sol-Gel Technologies
May 29, 2026
Initiated Coverage: Buy
Price Target: n/a
Current: $82.25
Upside: -
Protara Therapeutics
May 20, 2026
Rated: Buy
Price Target: n/a
Current: $3.92
Upside: -
Verrica Pharmaceuticals
May 12, 2026
Maintained: Buy
Price Target: $20
Current: $5.22
Upside: +283.14%
LENZ Therapeutics
May 11, 2026
Maintained: Buy
Price Target: $60
Current: $5.30
Upside: +1,032.08%
BioCryst Pharmaceuticals
May 6, 2026
Maintained: Buy
Price Target: $30
Current: $8.98
Upside: +234.08%
Supernus Pharmaceuticals
May 5, 2026
Maintained: Buy
Price Target: $65
Current: $44.63
Upside: +45.64%
May 4, 2026
Maintained: Buy
Price Target: €310.00 → €305.00
Current: €217.88
Upside: +39.99%
Apr 23, 2026
Rated: Buy
Price Target: $12 → $8
Current: $2.08
Upside: +284.62%
Mar 13, 2026
Maintained: Buy
Price Target: $165 → $175
Current: $128.41
Upside: +36.28%
Oct 30, 2025
Initiated Coverage: Buy
Price Target: n/a
Current: $6.34
Upside: -
Feb 26, 2025
Maintained: Buy
Price Target: n/a
Current: $18.44
Upside: n/a